Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fragile X Mental Retardation Protein | 21 | 2021 | 82 | 4.470 |
Why?
|
| Parkinson Disease | 18 | 2025 | 314 | 4.310 |
Why?
|
| Tremor | 17 | 2024 | 60 | 4.290 |
Why?
|
| Fragile X Syndrome | 19 | 2024 | 140 | 4.120 |
Why?
|
| Ataxia | 15 | 2024 | 51 | 3.640 |
Why?
|
| Heterozygote | 10 | 2022 | 72 | 1.830 |
Why?
|
| Postural Balance | 5 | 2025 | 62 | 1.470 |
Why?
|
| Trinucleotide Repeat Expansion | 7 | 2016 | 27 | 1.450 |
Why?
|
| Tinnitus | 4 | 2020 | 4 | 1.360 |
Why?
|
| Parkinsonian Disorders | 6 | 2016 | 91 | 1.320 |
Why?
|
| Humans | 57 | 2025 | 12240 | 1.310 |
Why?
|
| Middle Aged | 29 | 2025 | 4043 | 1.000 |
Why?
|
| Male | 36 | 2025 | 6815 | 0.990 |
Why?
|
| Female | 33 | 2025 | 6974 | 0.980 |
Why?
|
| Aged | 26 | 2025 | 4000 | 0.970 |
Why?
|
| Movement Disorders | 4 | 2016 | 32 | 0.900 |
Why?
|
| Health Status Disparities | 1 | 2025 | 30 | 0.870 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 34 | 0.860 |
Why?
|
| Phenotype | 8 | 2025 | 157 | 0.810 |
Why?
|
| Research Design | 5 | 2022 | 79 | 0.800 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.620 |
Why?
|
| Nootropic Agents | 1 | 2020 | 7 | 0.620 |
Why?
|
| Adult | 17 | 2025 | 3557 | 0.620 |
Why?
|
| Cognition | 3 | 2022 | 641 | 0.590 |
Why?
|
| Mutation | 5 | 2022 | 175 | 0.580 |
Why?
|
| Neurology | 1 | 2018 | 16 | 0.560 |
Why?
|
| Exercise Therapy | 1 | 2018 | 42 | 0.550 |
Why?
|
| Patient Selection | 1 | 2018 | 111 | 0.540 |
Why?
|
| Trinucleotide Repeats | 1 | 2018 | 9 | 0.540 |
Why?
|
| Memory Disorders | 2 | 2016 | 68 | 0.530 |
Why?
|
| Cognition Disorders | 3 | 2011 | 437 | 0.520 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2023 | 182 | 0.520 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 57 | 0.510 |
Why?
|
| Deafness | 3 | 2022 | 6 | 0.510 |
Why?
|
| Severity of Illness Index | 9 | 2020 | 423 | 0.490 |
Why?
|
| DNA Methylation | 1 | 2016 | 93 | 0.470 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 67 | 0.470 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 100 | 0.460 |
Why?
|
| Acoustic Stimulation | 1 | 2013 | 18 | 0.390 |
Why?
|
| Treatment Outcome | 6 | 2022 | 1478 | 0.370 |
Why?
|
| Quality of Life | 3 | 2025 | 261 | 0.370 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 2152 | 0.350 |
Why?
|
| Cohort Studies | 5 | 2023 | 827 | 0.340 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 74 | 0.340 |
Why?
|
| Executive Function | 1 | 2011 | 47 | 0.340 |
Why?
|
| Communication Disorders | 1 | 2011 | 2 | 0.340 |
Why?
|
| Neuropsychological Tests | 6 | 2022 | 558 | 0.340 |
Why?
|
| Cochlear Implantation | 2 | 2021 | 5 | 0.320 |
Why?
|
| Chromosomes, Human, X | 2 | 2009 | 5 | 0.320 |
Why?
|
| Speech Perception | 2 | 2021 | 18 | 0.320 |
Why?
|
| Shoulder Pain | 1 | 2010 | 24 | 0.320 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2009 | 1 | 0.310 |
Why?
|
| Chromosomes, Human, Y | 1 | 2009 | 1 | 0.310 |
Why?
|
| Activities of Daily Living | 3 | 2017 | 182 | 0.300 |
Why?
|
| Psychomotor Performance | 2 | 2025 | 85 | 0.300 |
Why?
|
| United States | 2 | 2025 | 989 | 0.290 |
Why?
|
| DNA Repeat Expansion | 2 | 2006 | 6 | 0.290 |
Why?
|
| Cognitive Dysfunction | 1 | 2014 | 449 | 0.290 |
Why?
|
| Case-Control Studies | 5 | 2021 | 256 | 0.290 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 546 | 0.280 |
Why?
|
| Pilot Projects | 2 | 2020 | 214 | 0.260 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 800 | 0.260 |
Why?
|
| Genetic Testing | 4 | 2014 | 29 | 0.260 |
Why?
|
| Observational Studies as Topic | 2 | 2025 | 14 | 0.260 |
Why?
|
| Dystonia | 1 | 2007 | 3 | 0.260 |
Why?
|
| Celiac Disease | 1 | 2007 | 3 | 0.260 |
Why?
|
| Cross-Sectional Studies | 4 | 2016 | 400 | 0.250 |
Why?
|
| Prospective Studies | 3 | 2025 | 817 | 0.250 |
Why?
|
| Cerebellar Ataxia | 1 | 2006 | 3 | 0.250 |
Why?
|
| Central Nervous System Agents | 1 | 2006 | 6 | 0.250 |
Why?
|
| Fetal Distress | 1 | 2006 | 1 | 0.250 |
Why?
|
| Pregnancy in Diabetics | 1 | 2006 | 2 | 0.250 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2006 | 9 | 0.240 |
Why?
|
| Incidence | 2 | 2020 | 338 | 0.240 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2006 | 11 | 0.240 |
Why?
|
| Seizures | 1 | 2006 | 35 | 0.240 |
Why?
|
| Child | 4 | 2015 | 614 | 0.240 |
Why?
|
| Parietal Lobe | 1 | 2025 | 11 | 0.230 |
Why?
|
| Huntington Disease | 1 | 2025 | 29 | 0.230 |
Why?
|
| Gait Ataxia | 1 | 2005 | 5 | 0.230 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 11 | 0.230 |
Why?
|
| Gait | 3 | 2016 | 195 | 0.230 |
Why?
|
| Disability Evaluation | 4 | 2016 | 105 | 0.220 |
Why?
|
| Retrospective Studies | 5 | 2015 | 1467 | 0.220 |
Why?
|
| Cerebral Cortex | 1 | 2025 | 77 | 0.220 |
Why?
|
| Prefrontal Cortex | 1 | 2025 | 66 | 0.220 |
Why?
|
| Brain | 3 | 2021 | 707 | 0.220 |
Why?
|
| Adolescent | 4 | 2015 | 989 | 0.220 |
Why?
|
| England | 2 | 2015 | 8 | 0.210 |
Why?
|
| RNA, Messenger | 3 | 2018 | 157 | 0.210 |
Why?
|
| Hyperglycinemia, Nonketotic | 1 | 2004 | 1 | 0.210 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2004 | 2 | 0.210 |
Why?
|
| Chorea | 1 | 2004 | 3 | 0.210 |
Why?
|
| Alleles | 2 | 2016 | 119 | 0.200 |
Why?
|
| Consensus | 2 | 2022 | 47 | 0.200 |
Why?
|
| Age of Onset | 3 | 2016 | 46 | 0.190 |
Why?
|
| Exercise | 2 | 2017 | 233 | 0.190 |
Why?
|
| Glucosylceramidase | 1 | 2022 | 3 | 0.180 |
Why?
|
| Multiple System Atrophy | 1 | 2022 | 22 | 0.180 |
Why?
|
| Subthalamic Nucleus | 1 | 2022 | 7 | 0.180 |
Why?
|
| Deep Brain Stimulation | 1 | 2022 | 15 | 0.180 |
Why?
|
| Walking Speed | 1 | 2022 | 13 | 0.180 |
Why?
|
| Prevalence | 2 | 2020 | 175 | 0.170 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2021 | 5 | 0.170 |
Why?
|
| Young Adult | 3 | 2015 | 863 | 0.170 |
Why?
|
| Ovary | 1 | 2021 | 15 | 0.170 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 5 | 0.170 |
Why?
|
| Menopause | 1 | 2021 | 41 | 0.170 |
Why?
|
| Cerebral Hemorrhage | 1 | 2021 | 37 | 0.160 |
Why?
|
| Brain Ischemia | 1 | 2021 | 35 | 0.160 |
Why?
|
| Biomechanical Phenomena | 3 | 2016 | 297 | 0.160 |
Why?
|
| Hearing Aids | 1 | 2020 | 1 | 0.160 |
Why?
|
| Hearing Loss, Unilateral | 1 | 2020 | 1 | 0.160 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 10 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 43 | 0.150 |
Why?
|
| Electroencephalography | 2 | 2013 | 32 | 0.150 |
Why?
|
| Genotype | 3 | 2016 | 169 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2022 | 156 | 0.150 |
Why?
|
| Time Factors | 2 | 2020 | 695 | 0.150 |
Why?
|
| Research Subjects | 1 | 2018 | 6 | 0.140 |
Why?
|
| Sample Size | 1 | 2018 | 9 | 0.140 |
Why?
|
| Academies and Institutes | 1 | 2018 | 6 | 0.140 |
Why?
|
| Motor Activity | 1 | 2020 | 175 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 40 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 79 | 0.130 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2017 | 8 | 0.130 |
Why?
|
| Ibuprofen | 1 | 2017 | 5 | 0.130 |
Why?
|
| Animals | 3 | 2021 | 2092 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 46 | 0.130 |
Why?
|
| Mosaicism | 1 | 2016 | 6 | 0.130 |
Why?
|
| Siblings | 1 | 2016 | 9 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2016 | 16 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 43 | 0.120 |
Why?
|
| Age Factors | 3 | 2021 | 350 | 0.120 |
Why?
|
| Computers | 1 | 2015 | 9 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2015 | 27 | 0.120 |
Why?
|
| Reaction Time | 1 | 2015 | 53 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2015 | 105 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 35 | 0.110 |
Why?
|
| Sex Factors | 3 | 2011 | 229 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 218 | 0.110 |
Why?
|
| Risk Factors | 3 | 2021 | 1049 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 151 | 0.100 |
Why?
|
| Hyperkinesis | 1 | 2013 | 8 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 10 | 0.100 |
Why?
|
| Auditory Pathways | 1 | 2013 | 1 | 0.100 |
Why?
|
| Psychoacoustics | 1 | 2013 | 3 | 0.100 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2013 | 4 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2013 | 29 | 0.100 |
Why?
|
| Cerebellar Diseases | 1 | 2013 | 3 | 0.100 |
Why?
|
| Auditory Perception | 1 | 2013 | 13 | 0.100 |
Why?
|
| Neuronal Plasticity | 1 | 2013 | 27 | 0.100 |
Why?
|
| Equipment Design | 1 | 2013 | 76 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2013 | 166 | 0.100 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 108 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2022 | 11 | 0.090 |
Why?
|
| Social Behavior Disorders | 1 | 2011 | 2 | 0.080 |
Why?
|
| Language Disorders | 1 | 2011 | 6 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2011 | 115 | 0.080 |
Why?
|
| Pedigree | 2 | 2008 | 27 | 0.080 |
Why?
|
| Point Mutation | 2 | 2008 | 19 | 0.080 |
Why?
|
| Neurologic Examination | 2 | 2006 | 49 | 0.070 |
Why?
|
| Atrophy | 2 | 2008 | 29 | 0.070 |
Why?
|
| Family Health | 2 | 2007 | 18 | 0.070 |
Why?
|
| Herpes Zoster | 1 | 2009 | 2 | 0.070 |
Why?
|
| Brown-Sequard Syndrome | 1 | 2009 | 2 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2009 | 320 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 726 | 0.070 |
Why?
|
| Palate, Soft | 1 | 2008 | 1 | 0.070 |
Why?
|
| Alexander Disease | 1 | 2008 | 1 | 0.070 |
Why?
|
| Heredodegenerative Disorders, Nervous System | 1 | 2008 | 2 | 0.070 |
Why?
|
| Genetic Carrier Screening | 1 | 2007 | 10 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 29 | 0.070 |
Why?
|
| Glutens | 1 | 2007 | 1 | 0.060 |
Why?
|
| Jejunum | 1 | 2007 | 4 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 13 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 14 | 0.060 |
Why?
|
| Biopsy | 1 | 2007 | 97 | 0.060 |
Why?
|
| Carbidopa | 1 | 2006 | 2 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 9 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2006 | 10 | 0.060 |
Why?
|
| Colorado | 1 | 2006 | 2 | 0.060 |
Why?
|
| Levodopa | 1 | 2006 | 14 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2006 | 21 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2006 | 14 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2006 | 46 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 81 | 0.060 |
Why?
|
| Registries | 1 | 2006 | 88 | 0.060 |
Why?
|
| Disease Progression | 3 | 2016 | 290 | 0.060 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2025 | 6 | 0.060 |
Why?
|
| Anxiety Disorders | 1 | 2006 | 84 | 0.060 |
Why?
|
| Pregnancy | 1 | 2006 | 193 | 0.060 |
Why?
|
| Cerebellum | 1 | 2005 | 17 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 30 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 40 | 0.060 |
Why?
|
| Health Surveys | 1 | 2005 | 38 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2006 | 312 | 0.060 |
Why?
|
| Prodromal Symptoms | 1 | 2024 | 11 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2004 | 14 | 0.050 |
Why?
|
| Stroke | 1 | 2005 | 117 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2023 | 17 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2023 | 25 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 87 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2023 | 110 | 0.050 |
Why?
|
| Metagenome | 1 | 2023 | 6 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 40 | 0.050 |
Why?
|
| Task Performance and Analysis | 2 | 2013 | 27 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 281 | 0.050 |
Why?
|
| Biomarkers | 1 | 2024 | 294 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 7 | 0.050 |
Why?
|
| Bacteria | 1 | 2022 | 34 | 0.040 |
Why?
|
| Genetic Background | 1 | 2021 | 2 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2021 | 5 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2021 | 10 | 0.040 |
Why?
|
| Fertility | 1 | 2021 | 12 | 0.040 |
Why?
|
| Life Style | 1 | 2022 | 102 | 0.040 |
Why?
|
| Hearing | 1 | 2021 | 7 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 24 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2021 | 36 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 464 | 0.040 |
Why?
|
| Cochlear Implants | 1 | 2020 | 6 | 0.040 |
Why?
|
| Noise | 1 | 2020 | 11 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 295 | 0.040 |
Why?
|
| Accelerometry | 1 | 2017 | 48 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2017 | 39 | 0.030 |
Why?
|
| Posture | 1 | 2016 | 20 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2016 | 66 | 0.030 |
Why?
|
| Video Recording | 1 | 2014 | 16 | 0.030 |
Why?
|
| Movement | 1 | 2013 | 58 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2013 | 46 | 0.020 |
Why?
|
| Mental Health | 1 | 2013 | 47 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 153 | 0.020 |
Why?
|
| Health Status | 1 | 2013 | 96 | 0.020 |
Why?
|
| Walking | 1 | 2013 | 108 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 338 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 72 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 60 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2011 | 31 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 115 | 0.020 |
Why?
|
| Geniculate Ganglion | 1 | 2009 | 1 | 0.020 |
Why?
|
| Superior Cervical Ganglion | 1 | 2009 | 1 | 0.020 |
Why?
|
| Pons | 1 | 2008 | 4 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2008 | 30 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 15 | 0.020 |
Why?
|
| Mass Screening | 1 | 2007 | 86 | 0.010 |
Why?
|
| California | 1 | 2004 | 27 | 0.010 |
Why?
|